ReviewFrontiers in public health2026
Pediatric hearing loss in the universal newborn hearing screening era: etiologies, risk indicators, and clinical phenotypes.
Review in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Childhood hearing loss poses significant developmental and public health challenges, impacting language acquisition, cognitive development, social participation, and educational outcomes. Universal newborn hearing screening (UNHS) has notably enhanced the early identification of congenital hearing loss, yet limitations persist. Mild, unilateral, delayed-onset, progressive, and certain neural forms of hearing loss may remain undetected during a single neonatal screening session. This review consolidates current evidence regarding the etiologies, risk indicators, and clinical features of pediatric hearing loss in the context of UNHS. Essential areas of focus encompass genetic causes and pharmacogenetic susceptibility, congenital cytomegalovirus infection, intrauterine nutritional and metabolic conditions, environmental and lifestyle exposures, alongside perinatal or neonatal intensive care unit-related risks such as prematurity, hyperbilirubinemia, hypoxia, infection, and exposure to ototoxic medications. These factors exhibit varied clinical implications: some serve as direct causes of hearing loss, while others signify heightened vulnerability to delayed-onset or progressive auditory dysfunction. The evidence highlights a developmental perspective on pediatric hearing loss, indicating that auditory risks may emerge postnatally and cannot be ruled out based solely on normal newborn screening results. Distinguishing between etiology, risk indicators, and clinical phenotype may enhance the identification of children requiring intensified post-screening monitoring. Future research should aim to refine causal evidence, genotype-phenotype correlations, and viable strategies for risk-based follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.